Breakthrough Clinical Results
Xenetic Biosciences announced the expansion of its research collaboration with The Scripps Research Institute (TSRI) to further develop its DNase I-based oncology platform. Preclinical studies using lymphoma and melanoma models showed that combining systemic DNase I (XBIO-015) with CAR-T cell therapy significantly reduced tumor burden and improved survival compared to CAR-T monotherapy. The expanded collaboration will include additional lymphoma and leukemia models. Xenetic is advancing this technology towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors. The DNase I works by degrading neutrophil extracellular traps (NETs), which suppress the immune system and promote cancer spread, thereby enhancing CAR-T cell efficacy.
Key Highlights
- Expanded collaboration with TSRI to advance DNase I-based oncology platform.
- Preclinical data shows improved efficacy of CAR-T cell therapy when combined with DNase I.
- DNase I degrades NETs, enhancing CAR-T cell infiltration and mitigating immunosuppression.
- Xenetic is advancing towards Phase 1 clinical trials for pancreatic carcinoma and other solid tumors.
Emerging Mechanism of Action
Emerging Mechanisms of Action for Cancer Treatment
Targeted Therapies
- Calcium electroporation (Ca-EP) shows promise with 33% objective response rate and 22% complete response rate
- Triptonide suppresses triple-negative breast cancer (TNBC) by triggering Twist1 degradation and reducing Notch1 expression
Natural Compounds
- Carvacrol demonstrates antitumor effects in prostate cancer by reducing IL-6 gene expression and decreasing signaling proteins like pSTAT3, pAKT, and pERK1/2
Kinase Inhibitors
- JNK inhibitor IX effectively inhibits pancreatic cancer growth through DNA damage resulting in G2 arrest mediated via p53 and p21
Microbiome-Based Approaches
- Gut microbiota significantly affects immunotherapy response with genera like Prevotella, Parabacteroides, Catenibacterium, and Turicibacter associated with positive responses
Novel Protein Targets
- Caldesmon and Centromere protein N (CENPN) are emerging as novel targets
- Integrin family proteins (ITGB1-8) show significant increases in pancreatic ductal adenocarcinoma
- Retinoblastoma (RB1) tumor suppressor regulates UV susceptibility across the genome
Advanced Delivery Systems
- Lipid-based delivery systems, polymer-based approaches, and advanced nanocarriers offer improved treatment for TNBC
- Poly(lactic-co-glycolic acid) nanoparticles (PLGA-NPs) encapsulating siRNA show promise for immune checkpoint silencing
Hormone Receptor Targeting
- The androgen receptor (AR) serves as both therapeutic target and prognostic biomarker in breast cancer
Immunotherapy Approaches
- Immune checkpoint inhibitors (ICIs) have transformed cancer treatment
- Sequencing treatments matters - improved responses to chemotherapy after immunotherapy have been reported
- CAR-T therapy received FDA approval in 2017, marking a major milestone
Epigenetic Modifications
- Histone deacetylase (HDAC) inhibitors show broad applicability across various cancer types
- METTL3, a key enzyme for N-methyladenosine (m6A) modification, is closely associated with various cancers
- The interplay between T cell metabolism and epigenetic modifications in tumors is being investigated
Multi-Target Approaches
- Multitarget drugs affecting multiple molecular pathways represent a promising strategy
- mTOR inhibitor everolimus has been sanctioned for ER+ breast cancer
- Poly (ADP-ribose) polymerase inhibitors show effectiveness in BRCA-related cancers
Precision Medicine Targets
-
Mendelian randomization analysis identified potential drug targets:
-
Prostate cancer: KDELC2, TNFRSF10B, SPINT2, GSTP1, and CTSS
-
Breast cancer: CPNE1, PDIA3, GDI2, ISLR2, and CTSF
-
Lung cancer: SFTPB, ICAM5, and FLRT3
Company drugs in pipeline
Xenetic Biosciences, Inc. Drug Pipeline Indications
I'm unable to provide specific information about Xenetic Biosciences, Inc. and their drug pipeline indications. The requested information about their investigational pharmaceutical candidates, therapeutic targets, disease areas, and clinical development stages is not available in the reference materials.
For accurate and current information about Xenetic Biosciences, Inc. and their drug development programs, I recommend:
- Visiting the company's official website
- Reviewing their investor relations materials
- Checking SEC filings such as annual reports (10-K) and quarterly reports (10-Q)
- Examining clinical trial registries like ClinicalTrials.gov
- Reading recent press releases from the company
These sources would provide comprehensive details about the company's therapeutic focus areas, pipeline candidates, and the current status of their drug development programs.